Patient-specific BIO-RSA (bony increased-offset reverse shoulder arthroplasty) for glenoid dysplasia (type C) osteoarthritis
Journal of Shoulder and Elbow Surgery · 2025
DOI: 10.1016/j.jse.2025.10.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Shoulder and Elbow Surgery, 2025. Verfasst von Mark Mouchantaf und 5 weiteren Autor:innen. Beteiligte Einrichtung: ICR-Institut de Chirurgie Réparatrice, Nice, France. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Shoulder, Osteoarthritis, Shoulder Joint, Glenoid Cavity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Glenoid dysplasia (Walch type-C) is characterized by a retroversion > 25° and predisposes the shoulder to degenerative osteoarthritis. Our purpose is to report the mid- to long-term clinical and radiologic outcomes of reverse shoulder arthroplasty (RSA) with a patient-specific structural humeral head autograft (bony increased-offset RSA [BIO-RSA] technique) for the treatment of glenoid dysplasia (Walch type C) osteoarthritis (OA). METHODS: This is a retrospective single-center case series of 45 shoulders (37 patients; mean age 76 ± 9 years) with type C glenoid OA (retroversion >25°) treated using a patient-specific BIO-RSA technique between 2012 and 2022. The cancellous bone graft was harvested from the proximal humerus using a bell saw. A wedge-shaped bone graft (12-25 mm) was crafted based on preoperative 3D planning (Blueprint; Tornier) and fixed to the native glenoid using a long (≥25-mm) central baseplate (Tornier Aequalis Reversed II)-either pegged (35 cases) or screwed (10 cases)-along with 4 peripheral screws. At least 10 mm of the central peg or screw was anchored in the native glenoid. Outcome measures included prosthesis survival, functional and subjective results, bone graft healing, and correction of glenoid retroversion and inclination. The mean follow-up was 6.5 years (range, 2-14 years). RESULTS: At the final follow-up, no reoperations or revisions were required, and no glenoid loosening or complications were observed. The mean retroversion correction was 30° ± 10° (from 37° ± 8° to 7° ± 7°), and the mean RSA angle improved from 13° ± 11° to 0° ± 5° (P 20-mm) did not influence healing. Incomplete retroversion correction (>10°) did not significantly impact functional outcomes, and the use of patient-specific guides (27% of cases) was not associated with improved correction. Constant-Murley scores and Subjective Shoulder Value improved from 40 ± 10 to 80 ± 12, and from 38% ± 13% to 91% ± 9%, respectively (P 45°) requiring thick bone grafts (>20-mm). The procedure provides excellent functional and subjective outcome, and the structural humeral autograft predictably heals the native glenoid, even in elderly patients (>80 years).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ICR-Institut de Chirurgie Réparatrice, Nice, France.
- ICR-Institut de Chirurgie Réparatrice, Nice, France. Electronic address: pr.boileau@icr-nice.com.
Zitieren
APA
Mouchantaf, M., Biegun, M., Schippers, P., Chelli, M., Secci, G., & Boileau, P. (2025). Patient-specific BIO-RSA (bony increased-offset reverse shoulder arthroplasty) for glenoid dysplasia (type C) osteoarthritis. Journal of Shoulder and Elbow Surgery. https://doi.org/10.1016/j.jse.2025.10.010
Vancouver
Mouchantaf M, Biegun M, Schippers P, Chelli M, Secci G, Boileau P. Patient-specific BIO-RSA (bony increased-offset reverse shoulder arthroplasty) for glenoid dysplasia (type C) osteoarthritis. Journal of Shoulder and Elbow Surgery. 2025. doi:10.1016/j.jse.2025.10.010
BibTeX
@article{Mouchantaf2025,
author = {Mouchantaf, Mark and Biegun, Manon and Schippers, Philipp and Chelli, Mikaël and Secci, Gregorio and Boileau, Pascal},
title = {Patient-specific BIO-RSA (bony increased-offset reverse shoulder arthroplasty) for glenoid dysplasia (type C) osteoarthritis},
journal = {Journal of Shoulder and Elbow Surgery},
year = {2025},
doi = {10.1016/j.jse.2025.10.010}
}
EUVIMED